Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
30 Janvier 2024 - 10:43PM
Business Wire
Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel
solution in modernizing foot and ankle surgery with the launch of
its FJ2000™ Power Console and Burr System designed for a wide range
of minimally invasive and open procedures in the foot and
ankle.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240130088714/en/
Figure 1: Paragon 28 FJ2000™ Power
Console (Graphic: Business Wire)
The FJ2000™ Power Console and Burr System is highly versatile
and designed for quick and efficient setup at the outset of each
procedure. The System has three pre-set options, including a low
speed, high torque setting designed to help reduce thermal necrosis
during bone and joint preparation and preserve healthy bone
healing.
The FJ2000™ offers single-use hand pieces and a substantial
selection of burrs and instruments in a sterile packed kit prepared
for immediate use. As a single-use option, the FJ2000™ brings
greater flexibility and speed to the surgeon while preventing
costly delays due to wear and tear and sterilization associated
with traditional power systems.
Prof. Dr. med. Hazibullah Waizy, commented, “This system is very
efficient from a workflow perspective. The combination of
adjustable speed and power settings and drilling function allows
surgeons to work precisely in a way most suitable for each unique
procedure. The sterile packed, single-use hand pieces and burrs are
dependable and allow me to turn cases quickly and effectively
without waiting for other instruments to become available.”
Paragon 28’s CEO, Albert DaCosta, commented, “The FJ2000™ brings
several benefits to the foot and ankle community, ranging from
health system cost, operating room efficiency, surgeon optionality
and ultimately improved patient outcomes. We are incredibly proud
to bring a modernized approach to the market that is truly
differentiated in so many ways.”
The FJ2000™ Power Console and Burr System bolsters Paragon 28’s
bunion and forefoot solutions offering, which includes the Gorilla®
Precision® Lapidus Plate, Phantom® Small Bone Intramedullary Nail,
Phantom® MIS System, Gorilla® Precision® MTP Plate, Phantom®
Metatarsal Shortening System, TenoTac®, Paratrooper™, and
HammerTube™. With this comprehensive portfolio, Paragon 28®
provides its customers with a single source to address their bunion
and forefoot needs.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward-looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward-looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and its Quarterly Reports on Form
10-Q, as updated periodically with its other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and Paragon 28 assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Disclaimer
Prof. Dr. med. Waizy may report consulting and royalty fees from
Paragon 28 in connection with the provision of product development
services to Paragon 28.
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240130088714/en/
Investor Contact Matthew Brinckman Senior Vice President,
Strategy and Investor Relations Phone: (720) 912-1332
mbrinckman@paragon28.com
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024